Integra lifesciences (IART) Scheduled to Post Quarterly Earnings on Wednesday

Integra lifesciences (NASDAQ:IART) is scheduled to be announcing its earnings results before the market opens on Wednesday, April 25th. Analysts expect the company to announce earnings of $0.49 per share for the quarter. Integra lifesciences has set its FY18 guidance at $2.25-2.35 EPS.

Integra lifesciences (NASDAQ:IART) last released its earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.08. The company had revenue of $368.60 million during the quarter, compared to the consensus estimate of $362.64 million. Integra lifesciences had a return on equity of 16.94% and a net margin of 5.45%. The firm’s quarterly revenue was up 44.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.52 earnings per share. On average, analysts expect Integra lifesciences to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

IART stock opened at $56.20 on Monday. The firm has a market cap of $4,437.62, a PE ratio of 29.12, a PEG ratio of 1.73 and a beta of 0.65. Integra lifesciences has a twelve month low of $41.51 and a twelve month high of $58.17. The company has a quick ratio of 1.51, a current ratio of 2.36 and a debt-to-equity ratio of 1.85.

In other Integra lifesciences news, VP Glenn Coleman sold 8,769 shares of the business’s stock in a transaction dated Wednesday, March 14th. The stock was sold at an average price of $56.10, for a total value of $491,940.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Joseph Vinhais sold 6,800 shares of the business’s stock in a transaction dated Friday, March 9th. The shares were sold at an average price of $54.13, for a total value of $368,084.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 79,765 shares of company stock valued at $4,314,208. 5.10% of the stock is owned by insiders.

A number of equities research analysts have recently weighed in on IART shares. Zacks Investment Research upgraded Integra lifesciences from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. JPMorgan Chase lifted their price objective on Integra lifesciences from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 11th. Oppenheimer reaffirmed a “buy” rating on shares of Integra lifesciences in a research note on Thursday, March 22nd. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $52.00 price objective on shares of Integra lifesciences in a research note on Friday, January 5th. Finally, BTIG Research initiated coverage on Integra lifesciences in a research note on Thursday, April 5th. They set a “neutral” rating and a $56.00 price objective for the company. Eleven equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Integra lifesciences currently has an average rating of “Hold” and an average price target of $55.82.

ILLEGAL ACTIVITY WARNING: This news story was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States and international trademark and copyright laws. The legal version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3381612/integra-lifesciences-iart-scheduled-to-post-quarterly-earnings-on-wednesday.html.

Integra lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Earnings History for Integra lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

MACOM Technology Solutions Holdings Inc  Position Lifted by Massachusetts Financial Services Co. MA
MACOM Technology Solutions Holdings Inc Position Lifted by Massachusetts Financial Services Co. MA
State Board of Administration of Florida Retirement System Acquires 953 Shares of CyrusOne
State Board of Administration of Florida Retirement System Acquires 953 Shares of CyrusOne
Rayonier Advanced Materials  to Issue Quarterly Dividend of $0.07
Rayonier Advanced Materials to Issue Quarterly Dividend of $0.07
First Trust Municipal High Income ETF  Declares $0.14 Monthly Dividend
First Trust Municipal High Income ETF Declares $0.14 Monthly Dividend
Hexcel  Holdings Cut by State Board of Administration of Florida Retirement System
Hexcel Holdings Cut by State Board of Administration of Florida Retirement System
Adient  Shares Sold by State Board of Administration of Florida Retirement System
Adient Shares Sold by State Board of Administration of Florida Retirement System


© 2006-2018 Ticker Report. Google+.